Sun Pharmaceutical Industries has reported an 11.8% year-on-year increase in consolidated sales to Rs 16,100 crore for the second quarter of FY27, while adjusted net profit rose to Rs 3,162 crore.
The country's largest pharmaceutical company reported EBITDA of Rs 4,743.9 crore, up 4.8% from the corresponding quarter last year. However, its EBITDA margin stood at 29.3%.
Profit before exceptional items and tax increased 6.3% to Rs 4,428.2 crore. Reported net profit stood at Rs 1,988.5 crore, while adjusted net profit was Rs 3,162 crore.
The company's global innovative medicines business generated sales of $356 million during the quarter, registering growth of 6.9% and contributing 21.1% to consolidated sales.
Sun Pharma invested Rs 778.4 crore in research and development during the quarter, equivalent to 4.8% of sales.
"Our performance during the quarter was driven by strong momentum in India, Emerging Markets and Rest of World. Among key developments, Ilumya is now approved in the U.S. for the treatment of adults with active psoriatic arthritis. Unloxcyt’s preferred NCCN recommendation reinforces its durable response and good tolerability in aCSCC.
"Beyond dermatology, we strengthened our cardiovascular portfolio through the licensing of lerodalcibep, a PCSK9 inhibitor, for markets outside US and China. We have started pre-launch activities across EU," said Kirti Ganorkar, Managing Director of Sun Pharma.
India remained a key growth engine for Sun Pharma, with domestic formulation sales jumping 17.3% year-on-year to Rs 5,552.3 crore during the quarter. The domestic business accounted for 34.5% of the company's consolidated sales.
For the first half of FY27, India formulation sales rose 16.6% to Rs 11,027.2 crore.
Sun Pharma retained its position as India's No. 1 pharmaceutical company, with its market share increasing to 8.6% from 8.3%, according to the Pharmarack MAT September 2026 report.
The company also ranked No. 1 in prescriptions across 12 doctor categories, according to the SMSRC July-September 2026 report.
Strengthening its domestic portfolio, Sun Pharma launched 14 new products during the quarter, taking the total number of launches in the first half of FY27 to 19.
Sun Pharma said integration planning for its Organon acquisition was progressing as scheduled across functions and workstreams.
Regulatory approvals have been secured in the majority of regions, with the remaining jurisdictions progressing according to plan.
For the six months ended September 30, 2026, Sun Pharma reported consolidated sales of Rs 31,283.6 crore, registering 11% year-on-year growth.
Global innovative medicines sales rose 9.8% to $707 million, accounting for 21.5% of consolidated sales.
EBITDA increased 3.8% to Rs 9,161.6 crore, with the margin at 29.1%. Profit before exceptional items and tax climbed 7% to Rs 8,731.1 crore.
Net profit for the first half stood at Rs 4,883.3 crore, while adjusted net profit rose 2.2% to Rs 6,251.5 crore.
R&D expenditure during the first half totalled Rs 1,604.8 crore, representing 5.1% of sales.
The company's quarterly performance highlights the continued strength of its India formulations business and growing contribution from global innovative medicines, even as it advances the integration of the Organon acquisition.
